News Release
ZymoGenetics to Host Conference Call and Webcast on May 4, 2010 to Discuss Q1 2010 Financial Results
April 16, 2010
SEATTLE, Apr 16, 2010 (BUSINESS WIRE) --ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today that it will report first quarter financial results on Tuesday, May 4, 2010 after market close. Following the announcement, members of the company's senior management will discuss the results and provide a corporate update.
Conference Call and Webcast Information
ZymoGenetics First Quarter 2010 Financial Results Conference Call will be held on May 4, 2010 at 4:30 p.m. Eastern Time and may be accessed at http://www.zymogenetics.com or by dialing (877) 407-0778 (International: 201-689-8565). Participants should dial in to the call approximately 10 minutes prior to the scheduled start time to register. A live audio webcast and slide presentation can be accessed by going to: http://www.zymogenetics.com. The webcast will be archived for 60 days.
For replay, please visit http://www.zymogenetics.com or use the following information:
- U.S. callers: (877) 660-6853
- International callers: (201) 612-7415
Replay passcode account #: 286
Conference ID #: 349411
About ZymoGenetics
ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases. ZymoGenetics has developed and is marketing RECOTHROM(R) Thrombin, topical (Recombinant) in the United States. ZymoGenetics has two product candidates in clinical development: PEG-Interferon lambda, being studied in collaboration with Bristol Myers Squibb (BMS) for treatment of hepatitis C virus (HCV) infection, and IL-21, being tested by us as a potential treatment for metastatic melanoma. In addition, ZymoGenetics has an anti-IL-31 monoclonal antibody in preclinical development, which it expects to test initially as a treatment for atopic dermatitis. Several of the product candidates previously identified through ZymoGenetics' discovery research efforts have been licensed to and are being developed by third parties, including Merck Serono and Novo Nordisk. ZymoGenetics is eligible to receive milestone payments and royalties related to these assets. For further information, visit www.zymogenetics.com.
SOURCE: ZymoGenetics, Inc.
ZymoGenetics, Inc.
Media and Investor Relations
Susan W. Specht, 206-442-6592
*****************************************
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding ZymoGenetics Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.